The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

The BCR-ABL T315I mutation confers resistance to currently licensed tyrosine kinase inhibitors in chronic myelogenous leukemia. However, the impact of this mutation on survival in early stages of disease, in chronic phase, has never been detailed. Using matched pair analysis, a cohort of 64 patients...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Nicolini, Franck E., Ibrahim, Amr R., Soverini, Simona, Martinelli, Giovanni, Müller, Martin C., Hochhaus, Andreas, Dufva, Inge H., Kim, Dong-Wook, Cortes, Jorge, Mauro, Michael J., Chuah, Charles, Labussière, Hélène, Morisset, Stéphane, Roche-Lestienne, Catherine, Lippert, Eric, Hayette, Sandrine, Peter, Senaka, Zhou, Wei, Maguer-Satta, Véronique, Michallet, Mauricette, Goldman, John, Apperley, Jane F., Mahon, François-Xavier, Marin, David, Etienne, Gabriel
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2013
Assuntos:
Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3789454/
https://ncbi.nlm.nih.gov/pubmed/23716543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.080234
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados